Article

Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel.

Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Journal of Controlled Release (impact factor: 5.73). 10/2005; 106(3):386-90. DOI:10.1016/j.jconrel.2005.05.020 pp.386-90
Source: PubMed

ABSTRACT To evaluate dexamethasone penetration to the eye after a short transcorneal and transscleral iontophoresis using a drug loaded hydrogel assembled on a portable iontophoretic device.
Iontophoresis of dexamethasone phosphate was studied in healthy rabbits using drug loaded disposable HEMA hydrogel sponges and portable iontophoretic device. Corneal iontophoretic administration was performed with a current intensity of 1 mA for 1 and 4 min. Transconjunctival and transscleral iontophoresis were performed twice for 2 min at two near places in the pars-plana area, on the conjunctival membrane or directly on the sclera. Dexamethasone concentrations were assayed using HPLC.
Dexamethasone levels in the rabbit cornea after a single transcorneal iontophoresis for 1 min were up to 30 fold higher compared to those obtained after frequent eye drop instillation. Also, high drug concentrations were obtained in the retina and sclera 4 h after transscleral iontophoresis.
A short low current non-invasive iontophoretic treatment using dexamethasone-loaded hydrogels has potential clinical value in increasing drug penetration to the anterior and posterior segments of the eye.

0 0
 · 
0 Bookmarks
 · 
32 Views
  • Source
    Article: Recent Advances in Ocular Drug Delivery Systems
    Kuno Noriyuki, Fujii Shinobu
    [show abstract] [hide abstract]
    ABSTRACT: Transport of drugs applied by traditional dosage forms is restricted to the eye, and therapeutic drug concentrations in the target tissues are not maintained for a long duration since the eyes are protected by a unique anatomy and physiology. For the treatment of the anterior segment of the eye, various droppable products to prolong the retention time on the ocular surface have been introduced in the market. On the other hand, direct intravitreal implants, using biodegradable or non-biodegradable polymer technology, have been widely investigated for the treatment of chronic vitreoretinal diseases. There is urgent need to develop ocular drug delivery systems which provide controlled release for the treatment of chronic diseases, and increase patient’s and doctor’s convenience to reduce the dosing frequency and invasive treatment. In this article, progress of ocular drug delivery systems under clinical trials and in late experimental stage is reviewed.
    Polymers. 01/2011;
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

2 min
 
4 min
 
Corneal iontophoretic administration
 
current intensity
 
Dexamethasone concentrations
 
Dexamethasone levels
 
dexamethasone penetration
 
dexamethasone phosphate
 
dexamethasone-loaded hydrogels
 
disposable HEMA hydrogel sponges
 
drug concentrations
 
drug penetration
 
frequent eye drop instillation
 
healthy rabbits
 
pars-plana area
 
rabbit cornea
 
sclera 4 h
 
short transcorneal
 
single transcorneal iontophoresis
 
transscleral iontophoresis